尼莫司汀治疗转移性软组织肉瘤的II期研究。欧洲癌症研究与治疗组织软组织和骨肉瘤小组。

Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

作者信息

Wagener D J, Somers R, Santoro A, Verweij J, Woll P J, Blackledge G, Schütte H J, Lentz M A, van Glabbeke M

机构信息

Division of Medical Oncology, Radboud University Hospital, Nijmegen, The Netherlands.

出版信息

Eur J Cancer. 1991;27(12):1604-5. doi: 10.1016/0277-5379(91)90424-c.

DOI:10.1016/0277-5379(91)90424-c

PMID:1782068

Abstract

The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.

摘要

欧洲癌症研究与治疗组织软组织和骨肉瘤研究组对33例符合条件的转移性软组织肉瘤患者进行了一项II期试验，每6周给予尼莫司汀100mg/m²。在31例可评估患者中，有3例（10%）出现部分缓解，持续时间分别为4.5个月、6个月和7.5个月，5例病情稳定。12例患者疾病进展，11例患者早期疾病进展。毒性主要包括白细胞减少、血小板减少以及恶心和呕吐。结论是尼莫司汀在软组织肉瘤中仅有轻微活性。